<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Després, Jean-Pierre</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Update on Dyslipidemia and Cardiovascular Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-29</style></pages><abstract><style  face="normal" font="default" size="100%">Despite the use of statins in patients who are dyslipidemic, residual risk of cardiovascular disease remains increased in many individuals [Libby P. J Am Coll Cardiol 2005]. New therapies are therefore needed to enhance the current standard of care for patients with high cardiometabolic risk [Chapman MJ et al. Eur Heart J 2009]. Key opinion leaders discussed the role of other available options for elevating high-density lipoprotein cholesterol.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>